Comparing Moderna’s mRNA-1083 and Pfizer’s dual-target mRNA vaccines for influenza and COVID-19

Comparing Moderna’s mRNA-1083 and Pfizer’s dual-target mRNA vaccines for influenza and COVID-19

Abstract This review examines Moderna’s mRNA-1083 and Pfizer/BioNTech’s mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. Both utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna’s mRNA-1083 showed superior immune responses, while Pfizer’...

Full description

Saved in:
Bibliographic Details
Main Authors: Adewunmi Akingbola, Abiodun Adegbesan, Kolade Adegoke, Courage Idahor, Petra Mariaria, Favour Peters, Raolat Adenike Salami, Olajide Ojo, Emmanuel Nwaeze, Owolabi Abdullahi, Joel Chuku
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-025-01145-6
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract This review examines Moderna’s mRNA-1083 and Pfizer/BioNTech’s mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. Both utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna’s mRNA-1083 showed superior immune responses, while Pfizer’s mRNA-1020/1030 performed well but was slightly less effective against influenza B. These vaccines simplify immunization strategies, enhance protection, and emphasize the need for global vaccine equity to prevent future outbreaks.
ISSN:2059-0105

Similar Items